AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1735651 — intervention group
Group type: EXPERIMENTAL
Intervention: Two types of head coverings (specific types not mentioned)
Number of subjects: 81
Study 1735651 — intervention group
Group type: COMPARATOR
Intervention: No head coverings (control group)
Number of subjects: 81
Study 1735651 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who reached normothermia in 5 hours or less (subgroup analysis)
Number of subjects: 81
Study 6384785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 59
Study 6384785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 59
Study 6384785 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 6384785 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (combined)
Number of subjects: 59
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-invitation group
Number of subjects: 40373
Study 31774954 — intervention group
Group type: COMPARATOR
Intervention: Mammography-only group
Number of subjects: 40373
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-invitation group (those who underwent MRI)
Number of subjects: 40373
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-invitation group (those who did not accept MRI)
Number of subjects: 40373
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 40373
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI recall for additional testing
Number of subjects: 40373
Study 31774954 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI biopsy
Number of subjects: 40373
Study 27718369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (single infusion of sub-anesthetic dose)
Number of subjects: 80
Study 26202488 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 8 years (long-term group)
Number of subjects: 4550
Study 26202488 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment for 5 years (cross-over group)
Number of subjects: 4550
Study 26202488 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab treatment (both groups)
Number of subjects: 4550
Study 24411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenotification postcard present
Number of subjects: 3010
Study 24411313 — intervention group
Group type: COMPARATOR
Intervention: Prenotification postcard absent
Number of subjects: 3010
Study 24411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaser present
Number of subjects: 3010
Study 24411313 — intervention group
Group type: COMPARATOR
Intervention: Teaser absent
Number of subjects: 3010
Study 24411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 3010
Study 24411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with teaser
Number of subjects: 3010
Study 24411313 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher response rates with postcard
Number of subjects: 3010
Study 23176888 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interventional treatment with mometasone furoate nasal spray (EIT group)
Number of subjects: 75
Study 23176888 — intervention group
Group type: COMPARATOR
Intervention: Postonset treatment with mometasone furoate nasal spray (POT group)
Number of subjects: 75
Study 23176888 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (placebo group)
Number of subjects: 75
Study 19384690 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0
Study 19384690 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal two-stage design
Number of subjects: 0
Study 17080503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput HPLC-FLD method for furosemide determination
Number of subjects: 0
Study 17080503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput HPLC-FLD method for norfloxacin determination
Number of subjects: 0
Study 17080503 — intervention group
Group type: EXPERIMENTAL
Intervention: Method applied to bioequivalence study of two furosemide-containing formulations
Number of subjects: 0
Study 15160519 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 124
Study 15160519 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 124
Study 11070330 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (800 microg/day over 2 weeks)
Number of subjects: 20
Study 11070330 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (400 microg acute administration)
Number of subjects: 20
Study 9041232 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg qid)
Number of subjects: 305
Study 9041232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (400 mg qid)
Number of subjects: 305
Study 9041232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 9041232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 305
Study 8178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg daily)
Number of subjects: 1724
Study 8178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg daily)
Number of subjects: 1724
Study 8178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (5.0 mg for 14 days per 28-day cycle)
Number of subjects: 1724
Study 8178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (10.0 mg for 14 days per 28-day cycle)
Number of subjects: 1724
Study 8178840 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (0.625 mg) alone
Number of subjects: 1724
Study 3228824 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg slow‐release isosorbide‐5‐mononitrate (ISMN SR) once daily
Number of subjects: 18
Study 3228824 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine SR twice daily
Number of subjects: 18
Study 3228824 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 18
Study 3228824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30012938 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost
Number of subjects: 46
Study 30012938 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 46
Study 28780559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy total diet replacement programme (810 kcal/d) for 8 weeks, followed by gradual food reintroduction and weekly behavioural support for 24 weeks.
Number of subjects: 0
Study 28780559 — intervention group
Group type: COMPARATOR
Intervention: Usual weight management interventions delivered in primary care.
Number of subjects: 0
Study 25000214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 52
Study 25000214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23810723 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (3 mg twice or 3 times daily) with azathioprine (1-2 mg/kg/day)
Number of subjects: 46
Study 23810723 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (40 mg/day tapered to 10 mg/day) with azathioprine (1-2 mg/kg/day)
Number of subjects: 46
Study 23810723 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label budesonide treatment after 6 months
Number of subjects: 46
Study 21081959 — intervention group
Group type: EXPERIMENTAL
Intervention: HKBBST
Number of subjects: 129
Study 19033530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 microg per day
Number of subjects: 60
Study 19033530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17519073 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts 37.5 mg
Number of subjects: 0
Study 15554316 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 158451
Study 15554316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass immunization of children
Number of subjects: 158451
Study 11464179 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized isotretinoin 0.4 mg/kg once daily without food (n = 300)
Number of subjects: 600
Study 11464179 — intervention group
Group type: COMPARATOR
Intervention: Standard isotretinoin 1.0 mg/kg per day in two divided doses with food (n = 300)
Number of subjects: 600
Study 9516704 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 0
Study 9516704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 0
Study 8795509 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (n = 46)
Number of subjects: 124
Study 8795509 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial catheter-directed thrombolysis (n = 78) with rt-PA or UK
Number of subjects: 124
Study 8795509 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial catheter-directed thrombolysis (n = 78)
Number of subjects: 124
Study 8795509 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic grafts
Number of subjects: 124
Study 2266236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M hydrochloric acid infusion
Number of subjects: 50
Study 2266236 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 50
Study 2266236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 M sodium bicarbonate infusion
Number of subjects: 50
Study 2266236 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 50
Study 6774493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (continuous perfusion for 48 hours, started < 8 hours after onset of symptoms)
Number of subjects: 60
Study 6774493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (continuous perfusion for 48 hours, started > 8 hours after onset of symptoms)
Number of subjects: 60
Study 6774493 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 60
Study 31060146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet, exercise, and diet plus exercise)
Number of subjects: 577
Study 31060146 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 577
Study 27883269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard six-dose AL treatment with milk (A)
Number of subjects: 33
Study 27883269 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-fortified maize porridge (B)
Number of subjects: 33
Study 27883269 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of AL
Number of subjects: 33
Study 27883269 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of AL
Number of subjects: 33
Study 25500293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 116
Study 25500293 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement
Number of subjects: 116
Study 26016869 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFAs
Number of subjects: 195
Study 26016869 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFAs
Number of subjects: 195
Study 26016869 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 195
Study 23278997 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting anticholinergic bronchodilation
Number of subjects: 2745
Study 23278997 — intervention group
Group type: COMPARATOR
Intervention: Control (no bronchodilation)
Number of subjects: 2745
Study 21901330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) with a dose of 0.7 μg/kg/h after initial dose and effect-site concentration (ESC) of fentanyl of 2 ng/ml
Number of subjects: 22
Study 21901330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) with ESC of fentanyl of 4 ng/ml
Number of subjects: 22
Study 17349805 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-sensitive control processes using a Stroop procedure
Number of subjects: 0
Study 17349805 — intervention group
Group type: COMPARATOR
Intervention: Awareness of context manipulation
Number of subjects: 0
Study 17349805 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to the predictive context dimension
Number of subjects: 0
Study 17349805 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative salience of target and predictive context dimensions
Number of subjects: 0
Study 16427168 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress fracture group
Number of subjects: 10
Study 16427168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 12951310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan GF-20 (Synvisc)
Number of subjects: 506
Study 12951310 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 506
Study 10848653 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d.
Number of subjects: 20
Study 10848653 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.d.
Number of subjects: 20
Study 9735411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) plus standard-dose external-beam whole-brain radiation treatment (WBRT)
Number of subjects: 14
Study 9735411 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified in detail)
Number of subjects: 14
Study 8014294 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 HME filter
Number of subjects: 30
Study 8014294 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 HME filter
Number of subjects: 30
Study 8014294 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 HME filter
Number of subjects: 30
Study 2902601 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol, given for a month
Number of subjects: 0
Study 2902601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29720209 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention
Number of subjects: 44
Study 29143624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based)
Number of subjects: 222
Study 29143624 — intervention group
Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC)
Number of subjects: 222
Study 29143624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based) for Muslim women
Number of subjects: 222
Study 29143624 — intervention group
Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC) for Muslim women
Number of subjects: 222
Study 29143624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Antenatal Care (CenteringPregnancy-based) for Christian women
Number of subjects: 222
Study 29143624 — intervention group
Group type: COMPARATOR
Intervention: Individual Antenatal Care (Focused Antenatal Care - FANC) for Christian women
Number of subjects: 222
Study 26482278 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (145 mg/m² as a 90-min intravenous infusion every 3 weeks)
Number of subjects: 852
Study 26482278 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 852
Study 26482278 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 852
Study 23225625 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) applied to the motor cortex during training.
Number of subjects: 0
Study 21707533 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 841
Study 21707533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients switched from galantamine)
Number of subjects: 841
Study 21707533 — intervention group
Group type: COMPARATOR
Intervention: Continuous placebo
Number of subjects: 841
Study 21707533 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment (subgroup analysis)
Number of subjects: 841
Study 17643535 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 22
Study 17643535 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 22
Study 16929307 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (3,4-dihydroxy-L-phenylalanine)
Number of subjects: 0
Study 16929307 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 12697596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 99
Study 12697596 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg
Number of subjects: 99
Study 12697596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 11054514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (V-CHART) delivering a total dose of 55.3 Gy in 33 fractions over 17 consecutive days
Number of subjects: 239
Study 11054514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy with mitomycin C (V-CHART+MMC) with additional administration of 20 mg/m2 MMC on day 5 of treatment
Number of subjects: 239
Study 11054514 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) with 70 Gy in 7 weeks in 35 fractions
Number of subjects: 239
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed prayer
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirected prayer
Number of subjects: 496
Study 9375429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents (prayers)
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of prayer by agents
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' belief in the power of prayer for others
Number of subjects: 496
Study 9375429 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects' conviction regarding group assignment
Number of subjects: 496
Study 7986838 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol (nonionic contrast medium)
Number of subjects: 438
Study 3291559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 37
Study 3291559 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 37
Study 31622131 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 3177
Study 28169575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician referral and 12-week exercise training program
Number of subjects: 147
Study 28169575 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 147
Study 26573025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program, 8 weeks, 90-minute sessions per week
Number of subjects: 40
Study 26573025 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 23206974 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose administered 5 years post-vaccination
Number of subjects: 663
Study 23206974 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose administered 10 years post-vaccination
Number of subjects: 663
Study 23206974 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose administered 15 years post-vaccination
Number of subjects: 663
Study 23206974 — intervention group
Group type: COMPARATOR
Intervention: No booster dose (5, 10, or 15 years post-vaccination)
Number of subjects: 663
Study 21435876 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg idebenone (Catena®)
Number of subjects: 21
Study 21435876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18491311 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.5 g daily)
Number of subjects: 81
Study 18491311 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (3.5 g daily)
Number of subjects: 81
Study 16570033 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5%
Number of subjects: 30
Study 16570033 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 30
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) with primary closure
Number of subjects: 534
Study 14681599 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) with patching
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline normal carotid arteries
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CAS <50%
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CAS 50% to 79%
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Late neurologic events
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Late contralateral CEA
Number of subjects: 534
Study 14681599 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 534
Study 11213546 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2.0 micrograms/kg) and atropine (0.01 mg/kg) as premedication
Number of subjects: 50
Study 11213546 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.2 microgram/kg/min) and atropine (0.01 mg/kg) as infusion
Number of subjects: 50
Study 9360253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 112
Study 9360253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 9360253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 1364952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-scleral panretinal cryocoagulation combined with cyclo-cryocoagulation
Number of subjects: 38
Study 1364952 — intervention group
Group type: COMPARATOR
Intervention: Cyclo-cryocoagulation
Number of subjects: 38